Cantor Fitzgerald Comments on Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Tourmaline Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($3.48) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($2.99) per share.

Tourmaline Bio (NASDAQ:TRML) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.06.

Other equities analysts have also issued research reports about the stock. BMO Capital Markets assumed coverage on shares of Tourmaline Bio in a research report on Friday, December 6th. They set an “outperform” rating and a $50.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of Tourmaline Bio in a research note on Wednesday, December 11th. Finally, Guggenheim reissued a “buy” rating on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $54.00.

Tourmaline Bio Trading Down 0.7 %

Shares of Tourmaline Bio stock opened at $17.88 on Wednesday. The business’s fifty day simple moving average is $22.18 and its 200 day simple moving average is $21.02. Tourmaline Bio has a 12 month low of $12.12 and a 12 month high of $48.31.

Institutional Investors Weigh In On Tourmaline Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new position in shares of Tourmaline Bio in the third quarter valued at $8,701,000. Blue Owl Capital Holdings LP lifted its holdings in shares of Tourmaline Bio by 18.5% in the second quarter. Blue Owl Capital Holdings LP now owns 1,715,401 shares of the company’s stock worth $22,060,000 after buying an additional 268,000 shares in the last quarter. State Street Corp boosted its position in shares of Tourmaline Bio by 25.6% in the third quarter. State Street Corp now owns 411,980 shares of the company’s stock valued at $10,592,000 after acquiring an additional 83,949 shares during the period. Renaissance Technologies LLC grew its stake in Tourmaline Bio by 184.9% during the second quarter. Renaissance Technologies LLC now owns 100,076 shares of the company’s stock valued at $1,287,000 after acquiring an additional 64,950 shares in the last quarter. Finally, Acuta Capital Partners LLC increased its holdings in Tourmaline Bio by 23.2% during the 3rd quarter. Acuta Capital Partners LLC now owns 332,095 shares of the company’s stock worth $8,538,000 after acquiring an additional 62,481 shares during the period. Institutional investors own 91.89% of the company’s stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.